Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Stupp regimen versus Stupp regimen for recurrent high-grade glioma
ChiCTR1800018983Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and temozolomide in glioma (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1800018983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018983.